J Biol Chem, Vol. 274, Issue 30, 21416-21424, July 23, 1999
Subcellular Localization and Internalization of the Four
Human Leptin Receptor Isoforms*
Valarie A.
Barr,
Kimberly
Lane, and
Simeon I.
Taylor
From the Diabetes Branch, NIDDK, National Institutes of Health,
Bethesda, Maryland 20892
 |
ABSTRACT |
There are four known isoforms of the human leptin
receptor (HLR) with different C-terminal cytoplasmic domains
(designated by the number of unique C-terminal amino acids). In cells
expressing HLR-5, -15, or -274, 15-25% of the leptin binding sites
were located at the plasma membrane. In contrast, in cells expressing
HLR-67, only 5% of the total binding sites were at the plasma
membrane. Immunofluorescent microscopy showed that all four isoforms
partially co-localized with calnexin and
-COP, markers of the
endoplasmic reticulum and the Golgi, respectively. All isoforms were
also detected in an unidentified punctate compartment. All isoforms were internalized via clathrin-mediated endocytosis, but at different rates. After 20 min at 37 °C, 45% of a bound cohort of labeled ligand had been internalized by HLR-15, 30% by HLR-67, 25% by HLR-274, and 15% by HLR-5. Degradation of internalized leptin occurred
in lysosomes. Overnight exposure to leptin down-regulated all isoforms,
but to a variable extent. HLR-274 displayed the greatest
down-regulation and also appeared to reach lysosomes more quickly than
the other isoforms. The faster degradation of HLR-274 may help to
terminate leptin signaling.
 |
INTRODUCTION |
Leptin is a peptide secreted primarily by adipose cells that
regulates appetite, energy metabolism, and neuroendocrine function. Leptin acts both centrally, presumably in the hypothalamus, and directly on peripheral tissues (1-3). Leptin binding activates its
receptor, a member of the cytokine receptor superfamily, which includes
receptors for interleukins, prolactin, growth hormone, and
erythropoietin (4, 5). As a result of differential mRNA splicing,
there are several isoforms of the leptin receptor with different
lengths and C-terminal sequences. The regions that are identical in all
the receptor isoforms include the extracellular ligand binding domain,
the transmembrane domain, and the first 29 amino acids in the
cytoplasmic domain. (4, 6-11).
Some cytokine receptors (e.g. receptors for growth hormone,
erythropoietin, and prolactin) form homodimers when activated by
ligand, while others form hetero-oligomers (12-14). Recent studies have shown that leptin receptors form homodimers, both in the presence
and absence of ligand (15, 16). Each leptin receptor binds one molecule
of leptin, resulting in a tetrameric complex composed of two receptors
and two leptin molecules. However, activation of the receptor is
thought to result from a ligand induced conformational change rather
than dimerization of the receptor (15, 17). All the leptin receptor
isoforms contain a "box 1" Janus kinase binding site in the
cytoplasmic domain. The longest form also contains a "box 2" motif
and putative STAT1 binding
sites (5, 10, 11, 18) and thus only the long form is able to activate
STAT proteins (18-20).
Receptor-mediated endocytosis is a well characterized mechanism for
selectively transporting nutrients, hormones, and growth factors into
cells. Often receptors are concentrated in clathrin-coated pits and
then internalized in clathrin-coated vesicles, although non-clathrin-mediated uptake of receptors also occurs (21, 22). Short
amino acid sequences in the cytoplasmic domains of receptors drive
receptor internalization. The best known signals are tyrosine-based motifs, although dileucine motifs also promote receptor endocytosis (22). A dileucine sequence is important for the internalization of
gp130, a subunit of the IL-6 receptor (23) that is structurally similar
to the leptin receptor (4, 5). Leucine pairs are also found in the
cytoplasmic domains of the four isoforms of the human leptin receptor,
but it is not known if they are important for receptor internalization.
Because little is known about the trafficking of the various isoforms
of the human leptin receptor, we inquired whether the different
cytoplasmic tails might affect targeting of the receptors to the plasma
membrane or affect their endocytosis. Since many interleukin receptors
require association with either gp130 or leukemia inhibitory factor
receptor for efficient internalization (12-14), we inquired whether
leptin receptors would be efficiently endocytosed in the absence of
other transfected subunits. Experiments in transiently transfected
COS-7 cells showed that there were large intracellular pools of all the
isoforms of the leptin receptor and that many of these intracellular
receptors resided in the biosynthetic pathway. While all of the
isoforms internalized ligand, there were differences in the rates of
endocytosis. Furthermore, the longest form of the receptor appeared to
be preferentially targeted to lysosomes after internalization.
 |
MATERIALS AND METHODS |
Unless otherwise noted, all chemicals were reagent grade from
Sigma. Restriction enzymes were obtained from Roche Molecular Biochemicals.
Constructs for Leptin Receptors--
Primers (pair 1, TGTGCCTTAGAGGATTATGGGTGTAC and CCACTTAAACCATAGCGAATC; pair 2, GCTGAGAAAATTCCTCAAAGC and GCTAGAGAAGCACTTGGTGAC) were used to obtain
two pieces containing the full-length coding sequence for HLR-274 from
human brain Marathon cDNA library (CLONTECH Laboratories, Inc., Palo Alto CA) by polymerase chain reaction using an
Expand Long Template kit (Roche Molecular Biochemicals). These pieces
were assembled in pcr-Script (Stratagene, La Jolla, CA) by restriction
digestion and ligation. The DNA sequence of this receptor was
determined using ABI PRISM dye terminator cycle sequencing with
AmpliTaq DNA polymerase (PE Applied Biosystems, Foster City, CA).
Oligonucleotides were synthesized (Integrated DNA Technologies, Inc.,
Coralville, IA) that contained the unique cytoplasmic sequences of
HLR-5 and HLR-15. Primers were used to obtain the C terminus of HLR-67
from a human fetal liver Marathon cDNA library
(CLONTECH). Standard molecular biology techniques were used to replace the C terminus of HLR-274 with these sequences. The complete receptor sequences were transferred to the expression vector, pCI-neo (Promega Corp., Madison, WI) by standard methods, and
their sequences were confirmed.
Northern Blots--
Strippable riboprobes were made from the
pCI-neo HLR-15 and -67 constructs, using Strip-EZ probe kit (Ambion
Inc., Austin, TX). A 190-base pair HLR-67 antisense probe was made by
cutting the plasmid within the unique cytoplasmic sequence at
nucleotide 2884 (numbering according to U664696 cDNA) with
NspI and transcribing with T3 RNA polymerase following the
instructions from the E-Z probe kit. A shorter 45-base pair HLR-15
antisense probe was made by cutting at nucleotide 2777 (numbering
according to U52913 cDNA) with BstNI and transcribing
with T3 RNA polymerase. Multiple tissue Northern blots
(CLONTECH) were hybridized in QuikHyb (Stratagene) with 1.25 × 106 cpm/ml HLR-67 probe at 68 °C
overnight. The blots were washed twice for 15 min in 2× SSC, 0.05 % (w/v) SDS at room temperature, followed by washing four times for 20 min in 0.1× SSC, 0.1% SDS (w/v) at 60 °C. The blots were then
exposed to BioMax MS film (Eastman Kodak Co., Rochester, NY) using a
TransScreen-HE intensifying screen (Eastman Kodak Co.) for 1 h.
Blots were stripped according to Strip-EZ instructions, re-exposed to
confirm the removal of the first probe, and reprobed with 0.5 × 106 cpm/ml HLR-15 riboprobe following the same procedure.
Cell Culture and Transfections--
COS-7 cells (ATCC, Fairfax
VA) were maintained in Dulbecco's modified Eagle's medium (DMEM)
(BioFluids Inc., Rockville, MD) with 10% fetal calf serum at 37 °C
in 95% air, 5% CO2. Cells were seeded at 3 × 105 cells/35-mm well 18 h before transfection using
liposome-mediated transfection. To transfect cells for the binding
studies, we used one of the following two protocols. LipofectAMINE
(Life Technologies, Inc.) was used for the binding studies shown in
Fig. 3. We followed the manufacturer's instructions using 2 µg of
plasmid DNA and 6 µl of LipofectAMINE reagent/well, incubated the
cells with this mixture for 5 h, and then replaced the medium.
Later experiments were done with cells transfected with LipofectAMINE
Plus (Life Technologies, Inc.) using 1 µg of plasmid DNA/6 µl of
Plus reagent and 4 µl of LipofectAMINE reagent/well with an
incubation time of 4 h.
For immunofluorescence studies, COS-7 cells were transfected using
calcium phosphate-mediated transfection (5 Prime-3 Prime Inc., Boulder,
CO) following manufacturer's instructions. We used 40 µg of DNA/ml
of transfection mixture, 4 h of incubation, and 2 min of glycerol shock.
Binding Assays--
All assays were performed 48 h after
transfection. To determine cell surface leptin binding, cells were
washed twice with ice-cold PBS and incubated in binding buffer (DMEM,
25 mM HEPES, pH 7.4, 1% (w/v) bovine serum albumin)
containing 20,000-30,000 cpm/well of 125I-leptin (NEN Life
Science Products) and various concentrations of cold leptin (PreproTech
Inc., Rocky Hill, NJ) for 8 h. The medium was removed, and the
cells were washed twice with cold PBS, followed by solubilization in 1 ml of 0.4 N NaOH. To determine total leptin binding in
extracts, cells were solubilized in binding buffer containing 0.15%
(w/v) digitonin, mixed with labeled and cold leptin, and then incubated
while rotating at 4 °C overnight. 0.05% (w/v)
-globulin and
12.5% (w/v) polyethylene glycol 8000 were added to precipitate
receptor-ligand complexes, which were pelleted by centrifugation
(16,000 × g for 3 min). The pellets were washed twice
in DMEM with 12.5% (w/v) polyethylene glycol 8000 and then counted.
To measure the internalization of a cohort of bound
125I-leptin, cells were washed and incubated with
125I-leptin in binding buffer for 8 h at 4 °C. The
media containing 125I-leptin were removed, the cells were
washed twice in cold PBS, and 1 ml of fresh binding buffer was added to
the cells. After incubation at 37 °C for various times, the media
were removed, incubated with 2% (w/v) trichloroacetic acid at 4 °C
overnight, and the trichloroacetic acid-insoluble proteins were
pelleted by centrifugation (16,000 × g for 10 min).
Cell surface leptin was removed by incubating the cells in DMEM, 25 mM HEPES, pH 3.0, twice for 7 min. This removed >95% of
the surface 125I-leptin. Finally, the cells were
solubilized with 0.4 N NaOH. Continuous uptake of leptin
was measured using the same procedure, except the initial binding was
only for 4 h and the cells were transferred to 37 °C in the
continued presence of ligand. The method of Larkin et al.
(24) was modified to measure 125I-leptin internalization in
K+-depleted medium. Briefly, transfected cells were
hypotonically shocked for 5 min, incubated for 10 min in HEPES-buffered
saline, and then pretreated with HEPES-buffered saline supplemented
with 1 mM CaCl2 or with 1 mM
CaCl2 and 10 mM KCl for 30 min. Continuous internalization of leptin was measured in HEPES buffer with 1% (w/v)
dialyzed bovine serum albumin, containing either 1 mM
CaCl2 or 1 mM CaCl2 plus 10 mM KCl. The efficacy of inhibition was determined by
inhibition of EGF internalization.
Continuous internalization of leptin was also measured in
leupeptin-treated cells. Transfected cells were pretreated with 500 µg/ml leupeptin in DMEM for 1 h. After prebinding labeled leptin
at 4 °C, continuous uptake of leptin was measured during 2 h at
37 °C as described above, but in the presence of 500 µg/ml leupeptin. The efficacy of the leupeptin treatment was determined by
monitoring the inhibition of EGF degradation.
Half-life Determination--
Transfected cells were labeled
overnight in DMEM without cysteine or methionine, but supplemented with
0.05 mCi of EasyTag Express Protein Labeling mix/ml medium (NEN Life
Science Products). Cells were chased in complete medium, washed, and
extracted in lysis buffer (1% (w/v) Triton X-100, 50 mM
Tris, pH 7.5, 300 mM NaCl, Complete Protease Inhibitor
Mixture (Roche Molecular Biochemicals)). The extracts were cleared by
centrifugation (16,000 × g for 30 min), and the leptin
receptors were immunoprecipitated overnight at 4 °C with 2 µg/ml
goat polyclonal anti-N-terminal antibody (Research Diagnostics, Inc.,
Flanders, NJ) and 25 µl of Protein G Ultra link beads (Pierce). The
beads were washed and made into gel samples, and proteins were
separated on 7.5% SDS-PAGE gels. The proteins were transferred to
nitrocellulose by standard methods (25), and the
35S-labeled proteins were visualized on BioMax MS film
(Eastman Kodak Co.) using a LE TransScreen (Eastman Kodak Co.) to
amplify the signal. The same blots were used to determine the amount of protein using a phosphor screen and PhosphorImager (Molecular Dynamics,
Sunnyvale, CA).
Immunofluorescence--
Cells were stained for
immunofluorescence as described previously (26). Briefly, transfected
COS-7 cells were fixed in 2% (v/v) formaldehyde in PBS, stained with
goat anti-N-terminal human leptin receptor antibody (12.5 µg/ml)
(Research Diagnostics, Inc., Flanders, NJ) in PBS containing 10% (v/v)
fetal calf serum and 0.075% (w/v) saponin, and then visualized with
lissamine rhodamine-conjugated donkey anti-goat IgG antibody (1:150)
(Jackson Immunoresearch Laboratories Inc., West Grove, PA). In the
co-localization experiments, the transfected cells were stained with a
mixture of the anti-leptin receptor antibody and either rabbit
anti-calnexin (1:200) (StressGen Biotechnologies Corp., Victoria,
British Columbia, Canada) or rabbit anti-
-COP (1:500). The
anti-
-COP antiserum was the kind gift of Jennifer
Lippincott-Schwartz. The rabbit antibodies were visualized with
FITC-conjugated swine anti-rabbit IgG antibody (1:200) (Dako Corp.,
Carpinteria, CA).
To observe the uptake of anti-receptor antibody, the transfected cells
were washed in cold PBS and then incubated with DMEM, 25 mM
HEPES (pH 7.5), 0.2% (w/v) bovine serum albumin containing 5 µg of
goat anti-N-terminal human leptin receptor antibody at 37 °C. In
some experiments, 1 µg/ml leptin or 100 µg/ml human transferrin was
included in the incubation. The cells were then fixed and stained with
rabbit anti-human transferrin antibody (1:300) (Roche Molecular
Biochemicals) and visualized with a mixture of lissamine
rhodamine-conjugated donkey anti-goat IgG antibody (1:200) (Jackson
Immunoresearch Laboratories) and FITC-conjugated swine anti-rabbit IgG
antibody (1:200) (Dako Corp.). To look for transport of the anti-leptin
receptor antibody to lysosomes, the transfected cells were pretreated
with 500 µg/ml leupeptin, and leupeptin was included in the antibody
incubation buffer. After fixation, the cells were stained with mouse
anti-LIMP II (CD 63) monoclonal antibody (1:250) (Immunotech,
Marseilles France) and visualized with a mixture of lissamine
rhodamine-conjugated donkey anti-goat IgG antibody and FITC-conjugated
donkey anti-mouse IgG antibody (1:200 each) (Jackson Immunoresearch Laboratories).
Cells were viewed in a Zeiss Axiophot inverted microscope (Carl Zeiss
Inc., Thornwood, NY). Images were captured with a PentaMAX camera
(Princeton Instruments Inc., Trenton, NJ) and IP Labs software (Scanalytics, Inc., Fairfax, VA) and processed with Adobe Photoshop (Adobe Systems Inc., Mountain View, CA).
 |
RESULTS |
We studied the subcellular distribution and the endocytic behavior
of the four known isoforms of the human leptin receptor (Fig.
1). Although the first 891 amino acids
are identical, the receptors differ after a splice site in the
cytoplasmic domain. We have identified each isoform by the number of
unique amino acids past this splice point.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
Human leptin receptor isoforms. The
receptors are differentially spliced at the C terminus resulting in
proteins with different cytoplasmic domains. The first 29 amino acids
are identical and include a box 1 motif. Each isoform is designated by
the number of unique C-terminal amino acids.
|
|
HLR-15 and -67 Are Expressed in Tissue--
Previous studies on
leptin receptors in mouse have suggested that only the shortest (HLR-5)
and longest isoforms (HLR-274) are actually expressed, while the other
isoforms were said to be produced at very low levels detectable only by
reverse transcription-polymerase chain reaction (27). Therefore, we
analyzed Northern blots to determine whether mRNA encoding HLR-15
and HLR-67 is expressed (Fig. 2). HLR-15
mRNA was detected in several tissues including liver, pancreas,
spleen, thymus, brain, and fetal lung, while HLR-67 mRNA was found
primarily in fetal liver. The restricted expression of HLR-67 suggests
that it may have a role in liver development or perhaps in
hematopoiesis.

View larger version (111K):
[in this window]
[in a new window]
|
Fig. 2.
Northern blot analysis of the expression of
HLR-15 and HLR-67. Northern blots of multiple adult and fetal
tissues were probed with isoform specific riboprobes. Both blots were
exposed for 1 h using a Kodak TransScreen intensifying screen.
A, HLR-15; B, HLR-67.
|
|
Leptin Binding in Cells Expressing the Four Isoforms of
HLR--
COS-7 cells were transiently transfected with expression
vectors encoding each of the HLR isoforms, and the binding of
125I-leptin was studied in both whole cell monolayers and
solubilized cell extracts. Steady-state binding was assayed 48 h
after transfection. Scatchard plots are shown for representative
binding studies for each isoform (Fig. 3,
A-D). Similar Kd values were
obtained for all the isoforms (average Kd = 0.27 nM ± 0.03); we did not detect any significant differences
in the apparent leptin binding affinities between cell surface and
solubilized receptors. Four separate transfection experiments were
averaged to obtain the total expression of each isoform (Fig.
3E) and the relative surface expression (Fig.
3F). There were 4-fold more total leptin binding sites in
cells transfected with HLR-5 than in cells transfected with other
receptor isoforms. In agreement with previous studies, HLR-5 had the
highest cell surface binding (18, 28), while HLR-274 and HLR-15 had
5-fold fewer surface receptors, and HLR-67 showed very little surface
binding of leptin. However, there were large intracellular pools of all
the receptor isoforms. About 75% of the total population of HLR-5 and
-15, about 85% of -274 was intracellular, and greater than 95% of the
HLR-67 were found within the cells. Thus, the increased surface
expression of HLR-5 is due primarily to the difference in receptor
expression rather than a difference in subcellular distribution.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 3.
Distribution of leptin binding sites in COS-7
cells transiently transfected with the four HLR isoforms. COS-7
cells were transiently transfected with expression vectors for HLR-5,
HLR-15, HLR-67, or HLR-274. A-D, leptin binding was
measured at the cell surface ( ) or in solubilized extracts ( ).
Each panel shows Scatchard plots of representative binding studies. The
inset on panel C shows the cell
surface binding on an expanded scale. E and F,
data from four experiments were used to estimate the total cellular
content of leptin binding sites (E) and the percentage of
binding sites at the cell surface (F). Error
bars indicate ± S.E.
|
|
Half-lives of the Four Isoforms of HLR--
Transfected cells were
labeled overnight with Easy Tag Express protein labeling mix and then
chased for various times to determine the half-lives of the different
isoforms. The amounts of 35S-labeled leptin receptor
paralleled the total number of leptin binding sites (Fig. 3), with
HLR-5 having the most labeled protein and HLR-67 the least (data not
shown). There were no significant differences in the rates at which the
different isoforms were degraded; all four isoforms had half-lives of
approximately 4 h (ranging from 3.25 h for HLR-274 to
4.5 h for HLR-5). Overnight incubation with leptin did not affect
the half-lives of any of the isoforms.
Subcellular Localization of HLR--
The subcellular distributions
of the different isoforms were visualized by immunofluorescence
microscopy. All isoforms could be detected by antibody labeling at the
cell surface in non-permeabilized cells (data not shown). In
permeabilized cells, all four isoforms showed similar staining patterns
(Fig. 4). Since most cell surface receptors pass through the endoplasmic reticulum (ER) and Golgi during
biosynthesis, we inquired whether we could detect leptin receptors in
these compartments. In a few cells, almost all the HLR-5 co-localized
with calnexin. However, in most transfected cells, HLR-5 partially
co-localized with calnexin, a marker of the ER (Fig.
5, A and B) and
-COP, a marker of Golgi and Golgi-derived vesicles (Fig. 5,
C and D). Similar distributions were observed in
cells transfected with the other isoforms, although extensive co-localization with calnexin was more common in cells expressing HLR-67 (data not shown). In addition to the receptor visualized in
these biosynthetic compartments, most cells contained some bright
peripheral punctate staining that did not co-localize with lysosomal
markers or with internalized transferrin (data not shown).

View larger version (111K):
[in this window]
[in a new window]
|
Fig. 4.
Immunofluorescent localization of the four
HLR isoforms. Transfected COS-7 cells were fixed, permeabilized,
and stained with goat anti-leptin receptor antibody, followed by
lissamine rhodamine-conjugated anti-goat antibody as described under
"Materials and Methods". A, HLR-5-transfected cells;
B, HLR-15-transfected cells; C,
HLR-67-transfected cells; D, HLR-274-transfected
cells.
|
|

View larger version (108K):
[in this window]
[in a new window]
|
Fig. 5.
HLR-5 in the biosynthetic pathway. COS-7
cells transiently transfected with HLR-5 were fixed, permeabilized, and
stained with a mixture of goat anti-leptin receptor and rabbit
anti-calnexin antibodies, followed by lissamine rhodamine-conjugated
anti-goat and FITC-conjugated anti-rabbit antibodies as described under
"Materials and Methods" (A and B).
Alternatively, the transfected cells were stained with a mixture of
goat anti-leptin receptor and rabbit anti- -COP antibodies, followed
by lissamine rhodamine-conjugated anti-goat and FITC-conjugated
anti-rabbit antibodies (C and D). A,
HLR-5 immunostaining; B, calnexin immunostaining;
C, HLR-5 immunostaining; D, -COP
immunostaining. Arrows show examples of punctate staining
that did not co-localize with either calnexin or -COP.
|
|
Internalization of the Four Isoforms of HLR--
Next, we studied
the endocytosis of recombinant leptin receptors.
125I-Leptin was bound to transiently transfected COS-7
cells for 6 h at 4 °C, the free leptin was removed, and the
bound label was allowed to internalize for various times at 37 °C.
Fig. 6A shows a representative
experiment demonstrating the internalization of a cohort of HLR-15 as
measured by 125I-leptin internalization. The amount of cell
surface label decreased during incubation at 37 °C, while the amount
of internalized label increased. Trichloroacetic acid-soluble counts
began to appear in the media after about 20 min and then increased
during the rest of the time course. Endocytosis of the four different
isoforms is compared in Fig. 6 (B-D). After 20 min at
37 °C the sum of internalized leptin plus trichloroacetic
acid-soluble cpm accounted for almost 50% of the bound
125I-leptin in HLR-15-transfected cells, 30% in
HLR-67-transfected cells, 25% in HLR-274-transfected cells, and 15%
in HLR-5-transfected cells. Transiently expressed insulin receptors
were endocytosed more rapidly than any of the leptin receptors (the sum
of internalized plus degraded insulin was 57% after 20 min at
37 °C), indicating that COS-7 cells are capable of efficient
internalization of large numbers of receptors and that the slow
internalization of HLR-5 was not due to an intrinsic limitation in the
endocytosis pathway. Continuous uptake of labeled leptin was blocked by
depleting K+, indicating that all the leptin receptor
isoforms were endocytosed via clathrin-coated pits (Fig.
7) (24).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 6.
Leptin internalization by the four receptor
isoforms. 125I-Leptin was bound to the transfected
cells at 4 °C, and the cells were washed at 4 °C to remove the
unbound ligand and then incubated at 37 °C for the indicated time.
The medium was removed and treated with trichloroacetic acid. The cells
were washed, surface 125I-leptin was removed by acid
stripping, and the remaining cells were solubilized in NaOH. Each
sample was counted. The x axis shows the percentage of the
starting cpm found in each location. Error bars
indicate ± S.E. A, internalization of a cohort of
125I-leptin bound to HLR-15 during 90 min at 37 °C; ,
acid-strippable 125I-leptin bound to the cell surface; ,
125I-leptin remaining cell associated after acid stripping
(intracellular leptin); , trichloroacetic acid-soluble
125I cpm released into the medium. B-F,
comparison of leptin internalization in cells transfected with
different receptor isoforms. Cells were transfected with HLR-5 ( ),
HLR-15 ( ), HLR-67 ( ), and HLR-274 ( ). B,
surface-bound 125I-leptin associated with the four receptor
isoforms. C, 125I-leptin remaining
cell-associated after acid stripping (intracellular leptin).
D, trichloroacetic acid-soluble cpm in the medium.
E, trichloroacetic acid-precipitable cpm in the medium.
F, sum of intracellular 125I-leptin and
trichloroacetic acid-soluble cpm in the medium.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 7.
Inhibition of leptin internalization by
K+ depletion. Transfected cells were
allowed to bind 125I-leptin for 4 h at 4 °C and
were then incubated in the continued presence of
125I-leptin for 120 min at 37 °C in medium with KCl
( ) or without KCl ( ). Cells were treated as described in Fig. 6
and "Materials and Methods." The graphs show the amount
of 125I-leptin remaining cell associated after acid
stripping (intracellular leptin) plus the trichloroacetic acid-soluble
cpm released into the medium. Error bars
indicate ± S.E. A, HLR-5-transfected cells;
B, HLR-15-transfected cells; C,
HLR-67-transfected cells; D, HLR-274-transfected
cells.
|
|
Further experiments were performed to study multiple rounds of ligand
internalization and receptor down-regulation. In continuous uptake
experiments, internalized leptin increased during the first hour at
37 °C and then remained constant for the next 4 h (Fig. 8A). After a 30-min lag,
trichloroacetic acid-soluble counts accumulated in the media (Fig.
8B). In these experiments, the pool of intact labeled leptin
available for binding was depleted by cells expressing HLR-5, making it
difficult to see the extent of ligand internalization. Therefore, cells
expressing HLR-5 were also studied in the presence of 30 ng of cold
leptin. At the 6-h time point, in all cases the soluble cpm accounted
for 80% of the sum of internalized plus degraded leptin, indicating
that leptin was efficiently degraded after endocytosis by all four
receptor isoforms. Leupeptin inhibited leptin and EGF degradation to
similar extents (70% inhibition for HLR-5, 62% for HLR-15, 55% for
HLR-67, 73% for HLR-274, and 56% for EGF), indicating that lysosomes
are the primary site for leptin degradation. At the end of the time
course, the sum of internalized plus degraded leptin was greater than
the amount of leptin initially bound to the cell surface. For HLR-5 and
HLR-274, the final sum was twice the amount initially bound, for HLR-15 the sum was 3 times, and for HLR-67 it was 5 times the amount initially
bound. Thus, receptors must continue to appear at the cell surface
during incubation at 37 °C. To study down-regulation of the
receptors, we examined the effect of longer leptin treatments on the
number of cell surface binding sites. Overnight incubation with
saturating amounts of leptin resulted in a 50-70% decrease in the
amount of 125I-leptin surface binding. The greatest
decrease was seen in cells transfected with HLR-274 (Fig.
9).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 8.
Continuous uptake of leptin. Cells
transfected with the different receptor isoforms were allowed to bind
125I-leptin for 4 h at 4 °C and were then incubated
with 125I-leptin for varying times (0-5 h). Cells were
treated as described in Fig. 6 and "Materials and Methods." The
amounts of 125I-leptin remaining cell-associated after acid
stripping (intracellular leptin) and trichloroacetic acid-soluble cpm
were compared for the four receptor isoforms. Error
bars indicate ± S.E. , HLR-5; , HLR-15; ,
HLR-5 plus 30 ng of cold leptin; , HLR-67; , HLR-274.
A, intracellular leptin. B, trichloroacetic
acid-soluble cpm.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 9.
Down-regulation of the 4 HLR isoforms.
Transfected cells were incubated in complete medium containing various
amounts of added leptin for 18 h. The cells were washed, and cell
surface leptin binding was measured. The amount of binding is shown in
comparison to the amount of binding found in cells that had not been
treated with leptin. Error bars indicate ± S.E. , HLR-5; , HLR-15; , HLR-67; , HLR-274.
|
|
Antibody Uptake--
To visualize the movement of leptin receptors
after internalization from the cell surface, we performed a series of
antibody uptake experiments. Antibody was bound to transfected cells at 4 °C and then internalized at 37 °C. The anti-receptor antibody we used was directed against amino acids 32-51 and did not compete with labeled leptin in binding studies (data not shown). Using this
approach, we compared the endocytosis pathway of HLR-15 with that taken
by transferrin (Fig. 10). As expected,
there was some co-localization of internalized antibody with
internalized transferrin, as both transferrin and leptin receptors are
internalized by clathrin-coated vesicles. However, after only 10 min of
uptake, much of the leptin receptor antibody had already separated from
structures containing transferrin (Fig. 10, A and
B). The punctate staining pattern observed after antibody
uptake was similar to the peripheral punctate staining seen in Fig. 4.
Furthermore, leptin receptor antibody did not concentrate in the
perinuclear compartment containing transferrin (Fig. 10, C
and D). The distribution of internalized antibody was not
affected by including saturating amounts of leptin during the
incubation at 37 °C (data not shown). Similar results were seen with
all four isoforms.

View larger version (104K):
[in this window]
[in a new window]
|
Fig. 10.
Visualization of anti-receptor antibody and
transferrin uptake in cells transfected with HLR-15.
HLR-15-transfected cells were incubated with anti-human leptin receptor
antibody and human transferrin for either 10 or 60 min. The cells were
then washed, fixed, and stained as described under "Materials and
Methods." 10-min uptake at 37 °C: A, internalized
anti-HLR antibody; B, internalized transferrin.
Arrows indicate representative examples of spots containing
both internalized antibody and transferrin. 60-min uptake at 37 °C:
C, internalized anti-HLR antibody; D,
internalized transferrin. Arrowheads indicate the probable
location of the perinuclear recycling endosome where transferrin
accumulates.
|
|
Anti-leptin receptor antibody was also internalized in the presence of
leupeptin to look for the arrival of receptor in lysosomes. After 90 min of antibody uptake in HLR-5-transfected cells, there was little
co-localization of a lysosomal marker, LIMP II, with antibodies bound
to HLR-5 (Fig. 11, A and
B). Similar results were obtained in cells transfected with
HLR-15 and HLR-67 (data not shown). However, in cells transfected with
HLR-274, there was much more co-localization of the internalized
antibody with the lysosomal marker (Fig. 11, D and
E). At later times, there was substantial co-localization of
anti-leptin receptor antibody with LIMP II in cells expressing any of
the four HLR isoforms (data not shown). Thus, it appears that HLR-274
arrives in lysosomes more quickly than other isoforms. Moreover, in
cells allowed to internalize a cohort of antibody and then chased
overnight in the absence of leupeptin, punctate antibody staining
was still visible in cells transfected with HLR-5, HLR-15, and HLR-67
but not in cells transfected with HLR-274. The more rapid degradation of antibody in cells transfected with HLR-274 supports the previous conclusion that HLR-274 is delivered more rapidly to lysosomes.

View larger version (95K):
[in this window]
[in a new window]
|
Fig. 11.
Dual labeling of internalized anti-receptor
antibody and LIMP II. Cells were transfected with either HLR-5 or
HLR-274, pretreated with leupeptin, and then incubated with anti-HLR
antibody for 90 min at 37 °C in the continued presence of leupeptin.
The cells were washed, fixed, and stained as described under
"Materials and Methods" to detect the internalized antibody and
LIMP II (CD 63), a lysosomal protein. Cells transfected with HLR-5:
A, internalized anti-HLR antibody; B, LIMP II.
Cells transfected with HLR-274: C, internalized anti- HLR
antibody; D, LIMP II. Arrows indicate
representative examples of spots containing internalized antibody that
also stain with anti-LIMP II antibody.
|
|
 |
DISCUSSION |
We studied the trafficking of the four known isoforms of the human
leptin receptor. The expression of two isoforms, HLR-5 and HLR-274, is
well documented (5, 27, 29-31). We have presented evidence that the
two other forms are also expressed in some tissues. The most striking
observation is that the steady-state distribution and internalization
of all four isoforms were very similar, but with some interesting
differences. In comparison to the other isoforms, relatively little
HLR-67 was found at the cell surface. In addition, the rates of
endocytosis varied, with HLR-15 being internalized the fastest and
HLR-5 the slowest. Furthermore, HLR-274 appeared be the most rapidly
transported to lysosomes and the most sensitive to down-regulation.
Binding and Signaling--
We found no significant differences in
the affinity of leptin binding among the isoforms of the human
receptor, just as previous studies found no differences in the mouse
isoforms (18). Human leptin levels have been reported to range from 7 to 10 ng/ml in lean humans (0.4-0.6 nM). According to our
estimates of the Kd of the leptin receptors
(~0.3 nM), at least half of the surface leptin
receptors should be occupied normally. Thus, even in the presence of
saturating amounts of ligand, the most that leptin receptor occupancy
could increase is 2-fold.
Only the longest isoform, HLR-274, is thought to be involved in control
of body weight (1, 4, 6, 19). After activation by leptin, the longest
mouse receptor isoform can mediate phosphorylation of the receptor as
well as Janus kinase-2, insulin receptor substrate-1, and STAT proteins
(32, 33). This leads to activation of STAT-dependent gene
transcription and increased mitogen-activated protein kinase activity
(18, 29, 34). Furthermore, C57Bl/Ks db/db mice, which
specifically lack only the long isoform of the leptin receptor, show
the same deficiencies as ob/ob mice which produce no leptin (7, 8). This suggests that the long isoform is responsible for
mediating most (if not all) biologically relevant actions of leptin. In
studies in transfected cells, the long isoform can promote cell
proliferation, while both HLR-5 (or the mouse equivalent) and HLR-67 have failed to elicit cellular responses (10, 18, 33). While
it has been shown that the shortest mouse isoform can stimulate
mitogen-activated protein kinase activity, the physiological relevance
of this signal has not yet been elucidated (28, 32). The preferential
trafficking of HLR-274 to lysosomes and its enhanced sensitivity to
down-regulation may be a way to terminate leptin-induced signals
transmitted by this isoform.
Localization--
There were large intracellular pools of all four
isoforms of the human leptin receptor. This result is supported by
other studies on the localization of endogenous receptor in brain. It has been shown that the endogenous long isoform of the leptin receptor
is found predominantly within the cell bodies of rat neurons, not at
the cell surface (35, 36). In addition, immunohistochemical localization studies using an antibody that recognizes all leptin receptor isoforms showed intracellular immunoreactivity in brain, including intense intracellular staining of the choroid plexus epithelium, where it is thought that most of the receptor is the shortest isoform (HLR-5) (36, 37). Electron microscopic examination of
the distribution of the endogenous long isoform in hypothalamic neurons
revealed that most of the intracellular receptors were in the Golgi
(38). These results suggest that the localization of transfected leptin
receptors is similar to the localization of endogenous leptin
receptors. In our studies, we observed leptin receptors in the Golgi,
but many transfected receptors were also detected in the ER. Misfolded
proteins are often retained in the ER (39-41), but the internal
receptors bound leptin with the same affinity as the surface receptors,
suggesting that they are not grossly misfolded. ER retention also
occurs when one or more subunits are absent from a multisubunit complex
(42), but there is no evidence that additional subunits are needed to
form either functional leptin receptors or to facilitate the transport
of the leptin receptor to the plasma membrane (16). The distribution of
leptin receptors is similar to that of related receptors for prolactin and erythropoietin (EPO-R), which are also found in intracellular pools
(43, 44). While 25% of HLR-5, HLR-15, and HLR-274 reached the cell
surface, 95% of the HLR-67 was retained in the ER. Although the reason
for this difference is not known, it is possible that HLR-67 possesses
ER retention signals not found in the other isoforms or, alternatively,
requires an additional subunit to facilitate exit from the ER.
Interestingly, all four isoforms were also seen in an unidentified
punctate compartment. Because a similar compartment was seen after
endocytosis of anti-receptor antibody, we conclude that this is
probably an endosomal compartment.
Half-lives--
The half-lives of all the isoforms were similar
and unchanged by exposure to leptin. However, the number of cell
surface binding sites was reduced by incubation with excess leptin.
This is reminiscent of results reported in studies of the EPO-R, where
the bulk of 35S-labeled receptor is a 68-kDa form whose
half-life is unaffected by EPO. However, a minor 78-kDa form of the
EPO-R appears to be the form found at the cell surface and shows a
dramatic decrease in half-life in response to EPO (45). Similarly, it
is possible that the half-lives of HLR we measured may represent
turnover of the large intracellular pool of receptors and therefore may not reflect turnover of cell surface receptors.
Endocytosis--
All the isoforms of HLR were internalized by a
clathrin-mediated mechanism, suggesting that there may a motif in the
common cytoplasmic region capable of interacting with AP-2, the plasma membrane adaptor complex (22, 46). However, the slow internalization of
HLR- 5 and the differences in the internalization rates suggest that
this is a relatively weak signal. HLR-15 and HLR-67 may be aided by
additional motifs or interactions with other proteins. HLR-15 possesses
a good consensus dileucine motif in its unique cytoplasmic tail, but
HLR-67 does not have any obvious endocytic signals. Even these two HLR
isoforms were internalized more slowly than other cytokine receptors,
including IL-6 receptor hetero-oligomers (23, 47), the growth hormone
receptor (48, 49), the prolactin receptor (43), and EPO-R (44, 45).
However, all of the leptin receptors were internalized more rapidly
than the IL-6 receptor in the absence of functional gp130 (47).
Eventually, the receptors arrived in lysosomes and leptin itself was
efficiently degraded there. Continuous exposure to ligand caused
down-regulation of the leptin receptors, but there were subtle
differences among the isoforms. HLR-5 showed the smallest loss of
surface binding sites, and HLR-274 showed the largest. Leptin receptors
were replenished at the cell surface during incubations at 37 °C. We
found large numbers of leptin receptors in intracellular compartments
and no visible leptin receptors in the classical recycling pathway defined by transferrin. Thus, it seems likely that most of the leptin
receptors appearing at the cell surface came from the intracellular pools rather than endocytosed receptors returning for multiple rounds
of ligand uptake. In a similar manner, endocytosed prolactin receptors
are replaced with receptors from intracellular stores (43).
Transcytosis of HLR-5--
Leptin transport from blood to brain is
specific and saturable (50-52). It has been suggested that HLR-5 may
serve as the transcytotic leptin transporter (51, 52). In our study,
HLR-5 showed no special intracellular trafficking, although our
continuous uptake experiments indicated that there is enough
internalization of this abundant isoform to transport substantial
quantities of leptin across a cell. Furthermore, the relative
insensitivity of this isoform to down-regulation suggests that it could
continue to internalize leptin even when serum leptin levels are
elevated. However, the degradation of most of the internalized leptin
and the delivery of receptor to lysosomes suggests that HLR-5 may not
be a transcytotic transporter. When the polymeric IgA receptor, a
bona fide transcytotic receptor, is expressed in
nonpolarized cells, the ligand is internalized and then re-exocytosed
with very little degradation (53). Further evidence against HLR-5 acting as the primary leptin transporter comes from the Koletsky rat,
which has a premature stop codon at amino acid 763 in the extracellular
domain of the leptin receptor (54). These animals have normal levels of
CSF leptin, suggesting that the Koletsky rat does not have a specific
transporter defect (52). While further work is needed, these studies do
not indicate that the main function of HLR-5 is to transport leptin
across the blood brain barrier.
Conclusions--
The differences among the cytoplasmic sequences
of the four isoforms of the human leptin receptor do not appear to
cause major differences in the localization or trafficking of these
receptors. The lack of unique trafficking of HLR-5 makes it unlikely
that this isoform functions as a transcytotic transporter. However, its
ability to internalize and deliver leptin to lysosomes indicates HLR-5
may be involved in leptin clearance. The relatively rapid degradation
of HLR-274 may be a way to terminate leptin signaling. It is
interesting that there are large intracellular pools of all of the
leptin receptors. We do not know if it is possible to stimulate release
of these receptors from their intracellular location to increase the
surface expression. Since leptin resistance is generally associated
with obesity, a drug that could increase the number of surface HLR-274
might provide an approach to increase leptin sensitivity and treat obesity.
 |
ACKNOWLEDGEMENT |
We are grateful to Dr. Carol Renfrew Haft for
critical reading of the manuscript and helpful discussions.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Branch Chief, Diabetes
Branch, NIDDK, NIH, Bldg. 10 9S213, 10 Center Dr., Bethesda, MD 20892. Tel.: 301-496-4658; Fax: 301-402-0573; E-mail:
sit@box-s.nih.gov.
 |
ABBREVIATIONS |
The abbreviations used are:
STAT, signal
transducers and activators of transcription;
HLR, human leptin
receptor;
IL, interleukin;
PBS, phosphate-buffered saline;
ER, endoplasmic reticulum;
EGF, epidermal growth factor;
LIMP, lysosomal
integral membrane protein;
EPO, erythropoietin;
EPO-R, erythropoietin
receptor;
PAGE, polyacrylamide gel electrophoresis;
FITC, fluorescein
isothiocyanate;
DMEM, Dulbecco's modified Eagle's medium.
 |
REFERENCES |
| 1.
|
Friedman, J. M.,
and Halaas, J. L.
(1998)
Nature
395,
763-770[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Considine, R. V.,
and Caro, J. F.
(1996)
Horm. Res.
46,
249-256[Medline]
[Order article via Infotrieve]
|
| 3.
|
Zhang, Y.,
Proenca, R.,
Maffei, M.,
Barone, M.,
Leopold, L.,
and Friedman, J. M.
(1994)
Nature
372,
425-432[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Tartaglia, L. A.
(1997)
J. Biol. Chem.
272,
6093-6096[Free Full Text]
|
| 5.
|
Tartaglia, L. A.,
Dembski, M.,
Weng, X.,
Deng, N.,
Culpepper, J.,
Devos, R.,
Richards, G. J.,
Campfield, L. A.,
Clark, F. T.,
Deeds, J.,
Muir, C.,
Sanker, S.,
Moriarty, A.,
Moore, K. J.,
Smutko, J. S.,
Mays, G. G.,
Woolf, E. A.,
Monroe, C. A.,
and Tepper, R. I.
(1995)
Cell
83,
1263-1271[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Friedman, J. M.
(1997)
Eur. J. Med. Res.
2,
7-13[Medline]
[Order article via Infotrieve]
|
| 7.
|
Lee, G. H.,
Proenca, R.,
Montez, J. M.,
Carroll, K. M.,
Darvishzadeh, J. G.,
Lee, J. I.,
and Friedman, J. M.
(1996)
Nature
379,
632-635[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Chen, H.,
Charlat, O.,
Tartaglia, L. A.,
Woolf, E. A.,
Weng, X.,
Ellis, S. J.,
Lakey, N. D.,
Culpepper, J.,
Moore, K. J.,
Breitbart, R. E.,
Duyk, G. M.,
Tepper, R. I.,
and Morgenstern, J. P.
(1996)
Cell
84,
491-495[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Chua, S. C., Jr.,
Chung, W. K.,
Wu-Peng, X. S.,
Zhang, Y.,
Liu, S. M.,
Tartaglia, L.,
and Leibel, R. L.
(1996)
Science
271,
994-996[Abstract]
|
| 10.
|
Bennett, B. D.,
Solar, G. P.,
Yuan, J. Q.,
Mathias, J.,
Thomas, G. R.,
and Matthews, W.
(1996)
Curr. Biol.
6,
1170-1180[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Cioffi, J. A.,
Shafer, A. W.,
Zupancic, T. J.,
Smith-Gbur, J.,
Mikhail, A.,
Platika, D.,
and Snodgrass, H. R.
(1996)
Nat. Med.
2,
585-589[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Finidori, J.,
and Kelly, P. A.
(1995)
J. Endocrinol.
147,
11-23[Abstract/Free Full Text]
|
| 13.
|
Ihle, J. N.
(1995)
Nature
377,
591-594[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Kishimoto, T.,
Taga, T.,
and Akira, S.
(1994)
Cell
76,
253-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Devos, R.,
Guisez, Y.,
Van der Heyden, J.,
White, D. W.,
Kalai, M.,
Fountoulakis, M.,
and Plaetinck, G.
(1997)
J. Biol. Chem.
272,
18304-18310[Abstract/Free Full Text]
|
| 16.
|
Nakashima, K.,
Narazaki, M.,
and Taga, T.
(1997)
FEBS Lett.
403,
79-82[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Fong, T. M.,
Huang, R. R.,
Tota, M. R.,
Mao, C.,
Smith, T.,
Varnerin, J.,
Karpitskiy, V. V.,
Krause, J. E.,
and Van der Ploeg, L. H.
(1998)
Mol. Pharmacol.
53,
234-240[Abstract/Free Full Text]
|
| 18.
|
Baumann, H.,
Morella, K. K.,
White, D. W.,
Dembski, M.,
Bailon, P. S.,
Kim, H.,
Lai, C. F.,
and Tartaglia, L. A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8374-8378[Abstract/Free Full Text]
|
| 19.
|
White, D. W.,
and Tartaglia, L. A.
(1996)
Cytokine Growth Factor Rev.
7,
303-309[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Ghilardi, N.,
and Skoda, R. C.
(1997)
Mol. Endocrinol.
11,
393-399[Abstract/Free Full Text]
|
| 21.
|
Schwartz, A. L.
(1995)
Pediatr. Res.
38,
835-843[Medline]
[Order article via Infotrieve]
|
| 22.
|
Mukherjee, S.,
Ghosh, R. N.,
and Maxfield, F. R.
(1997)
Physiol. Rev.
77,
759-803[Abstract/Free Full Text]
|
| 23.
|
Dittrich, E.,
Rose-John, S.,
Gerhartz, C.,
Mullberg, J.,
Stoyan, T.,
Yasukawa, K.,
Heinrich, P. C.,
and Graeve, L.
(1994)
J. Biol. Chem.
269,
19014-19020[Abstract/Free Full Text]
|
| 24.
|
Larkin, J. M.,
Brown, M. S.,
Goldstein, J. L.,
and Anderson, R. G.
(1983)
Cell
33,
273-285[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Towbin, H.,
Staehelin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4350-4354[Abstract/Free Full Text]
|
| 26.
|
Haft, C. R.,
Klausner, R. D.,
and Taylor, S. I.
(1994)
J. Biol. Chem.
269,
26286-26294[Abstract/Free Full Text]
|
| 27.
|
Fei, H.,
Okano, H. J.,
Li, C.,
Lee, G. H.,
Zhao, C.,
Darnell, R.,
and Friedman, J. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7001-7005[Abstract/Free Full Text]
|
| 28.
|
Murakami, T.,
Yamashita, T.,
Iida, M.,
Kuwajima, M.,
and Shima, K.
(1997)
Biochem. Biophys. Res. Commun.
231,
26-29[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Ghilardi, N.,
Ziegler, S.,
Wiestner, A.,
Stoffel, R.,
Heim, M. H.,
and Skoda, R. C.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
6231-6235[Abstract/Free Full Text]
|
| 30.
|
Luoh, S. M.,
Di Marco, F.,
Levin, N.,
Armanini, M.,
Xie, M. H.,
Nelson, C.,
Bennett, G. L.,
Williams, M.,
Spencer, S. A.,
Gurney, A.,
and de Sauvage, F. J.
(1997)
J. Mol. Endocrinol.
18,
77-85[Abstract/Free Full Text]
|
| 31.
|
Kielar, D.,
Clark, J. S.,
Ciechanowicz, A.,
Kurzawski, G.,
Sulikowski, T.,
and Naruszewicz, M.
(1998)
Metabolism
47,
844-847[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Bjorbaek, C.,
Uotani, S.,
da Silva, B.,
and Flier, J. S.
(1997)
J. Biol. Chem.
272,
32686-32695[Abstract/Free Full Text]
|
| 33.
|
Takahashi, Y.,
Okimura, Y.,
Mizuno, I.,
Takahashi, T.,
Kaji, H.,
Uchiyama, T.,
Abe, H.,
and Chihara, K.
(1996)
Biochem. Biophys. Res. Commun.
228,
859-864[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Vaisse, C.,
Halaas, J. L.,
Horvath, C. M.,
Darnell, J. E., Jr.,
Stoffel, M.,
and Friedman, J. M.
(1996)
Nat. Genet.
14,
95-97[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Baskin, D. G.,
Schwartz, M. W.,
Seeley, R. J.,
Woods, S. C.,
Porte, D., Jr.,
Breininger, J. F.,
Jonak, Z.,
Schaefer, J.,
Krouse, M.,
Burghardt, C.,
Campfield, L. A.,
Burn, P.,
and Kochan, J. P.
(1999)
J. Histochem. Cytochem.
47,
353-362[Abstract/Free Full Text]
|
| 36.
|
Shioda, S.,
Funahashi, H.,
Nakajo, S.,
Yada, T.,
Maruta, O.,
and Nakai, Y.
(1998)
Neurosci. Lett.
243,
41-44[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Couce, M. E.,
Burguera, B.,
Parisi, J. E.,
Jensen, M. D.,
and Lloyd, R. V.
(1997)
Neuroendocrinology
66,
145-150[Medline]
[Order article via Infotrieve]
|
| 38.
|
Diano, S.,
Kalra, S. P.,
and Horvath, T. L.
(1998)
J. Neuroendocrinol.
10,
647-650[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Cresswell, P.,
and Hughes, E. A.
(1997)
Curr. Biol.
7,
R552-R555[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Klausner, R. D.,
and Sitia, R.
(1990)
Cell
62,
611-614[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Lodish, H. F.
(1988)
J. Biol. Chem.
263,
2107-2110[Free Full Text]
|
| 42.
|
Klausner, R. D.,
Lippincott-Schwartz, J.,
and Bonifacino, J. S.
(1990)
Annu. Rev. Cell Biol.
6,
403-431[CrossRef]
|
| 43.
|
Genty, N.,
Paly, J.,
Edery, M.,
Kelly, P. A.,
Djiane, J.,
and Salesse, R.
(1994)
Mol. Cell. Endocrinol.
99,
221-228[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Levin, I.,
Cohen, J.,
Supino-Rosin, L.,
Yoshimura, A.,
Watowich, S. S.,
and Neumann, D.
(1998)
FEBS Lett
427,
164-170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Sawyer, S. T.,
and Hankins, W. D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
6849-6853[Abstract/Free Full Text]
|
| 46.
|
Hirst, J.,
and Robinson, M. S.
(1998)
Biochim. Biophys. Acta
1404,
173-193[Medline]
[Order article via Infotrieve]
|
| 47.
|
Dittrich, E.,
Haft, C. R.,
Muys, L.,
Heinrich, P. C.,
and Graeve, L.
(1996)
J. Biol. Chem.
271,
5487-5494[Abstract/Free Full Text]
|
| 48.
|
Allevato, G.,
Billestrup, N.,
Goujon, L.,
Galsgaard, E. D.,
Norstedt, G.,
Postel-Vinay, M. C.,
Kelly, P. A.,
and Nielsen, J. H.
(1995)
J. Biol. Chem.
270,
17210-17214[Abstract/Free Full Text]
|
| 49.
|
Harding, P. A.,
Wang, X.,
Okada, S.,
Chen, W. Y.,
Wan, W.,
and Kopchick, J. J.
(1996)
J. Biol. Chem.
271,
6708-6712[Abstract/Free Full Text]
|
| 50.
|
Banks, W. A.,
Kastin, A. J.,
Huang, W.,
Jaspan, J. B.,
and Maness, L. M.
(1996)
Peptides
17,
305-311[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Golden, P. L.,
Maccagnan, T. J.,
and Pardridge, W. M.
(1997)
J. Clin. Invest.
99,
14-18[Medline]
[Order article via Infotrieve]
|
| 52.
|
Wu-Peng, X. S.,
Chua, S. C., Jr.,
Okada, N.,
Liu, S. M.,
Nicolson, M.,
and Leibel, R. L.
(1997)
Diabetes
46,
513-518[Abstract]
|
| 53.
|
Deitcher, D. L.,
Neutra, M. R.,
and Mostov, K. E.
(1986)
J. Cell Biol.
102,
911-919[Abstract/Free Full Text]
|
| 54.
|
Takaya, K.,
Ogawa, Y.,
Hiraoka, J.,
Hosoda, K.,
Yamori, Y.,
Nakao, K.,
and Koletsky, R. J.
(1996)
Nat. Genet.
14,
130-131[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit